All Articles

The FDA has granted priority review to Merck’s supplemental Biologics License Application for the anti-PD–1 agent pembrolizumab as monotherapy for certain patients with high-risk, non-muscle invasive bladder cancer who are ineligible for or have elected not to undergo cystectomy.

Navigators are champions for patients. Our work has the potential to keep patients engaged, educated, empowered, as well as safe from infections during chemotherapy.

The CDC marks the 10-year anniversary of its highly successful program: Preventing Infections in Cancer Patients.

A study of unmet needs of cancer survivors and the role of their survivorship programs.

Navigators play a vital role in outreach to underserved communities by providing access to cancer care.

The CAPE program provides pertinent patient education, best practice information, and resources to patients at their most relevant time in their journey.

The updated National Comprehensive Cancer Network (NCCN) guideline for non–small-cell lung cancer (NSCLC; version 3.2019) is focused on improving patient outcomes with immunotherapy.

Approximately 25% of children, adolescents, and young adults with advanced cancer were eligible for a targeted therapy after genotyping of their tumors in the Pediatric Molecular Analysis for Therapy Choice (MATCH) clinical trial.

Reprogramming patients’ immune cells to treat their cancer has become the front line of cancer therapy, with chimeric antigen receptor (CAR) T-cell therapy now approved by the FDA for several blood cancers.